ATP2C1 blockers(ATPase secretory pathway Ca2+ transporting 1 blockers), GABRA1 agonists(gamma-aminobutyric acid type A receptor subunit alpha1 agonists), GLRA1 agonists(glycine receptor alpha 1 agonists)

Therapeutic Areas

Other DiseasesNeoplasmsNervous System Diseases+ [2]

Active Indication

AnesthesiaBreast CancerReperfusion Injury+ [1]

Inactive Indication-

Originator Organization

AbbVie, Inc.

Active Organization

Stony Brook University Hospital

AbbVie, Inc.

Maruishi Pharmaceutical Co., Ltd.

+ [2]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (20 Apr 1990),

Anesthesia

Regulation-

Structure/Sequence

Molecular FormulaC4H3F7O

InChIKeyDFEYYRMXOJXZRJ-UHFFFAOYSA-N

CAS Registry28523-86-6

1,193

Clinical Trials associated with Sevoflurane

NCT07608900

/ Not yet recruitingNot ApplicableIIT

Effect of Pre-emptive Local Anesthesia on Sevoflurane Consumption, Agent Uptake, and Carbon Footprint in Pediatric Day-case Dental General Anesthesia: A Prospective Randomized Controlled Trial

This study will evaluate whether pre-emptive local anesthesia reduces sevoflurane consumption during pediatric day-case dental treatment performed under general anesthesia.
Children aged 4 to 12 years scheduled for elective dental treatment under general anesthesia will be included. Participants will be assigned to either receive pre-emptive local anesthesia before the dental procedure or receive no pre-emptive local anesthesia. General anesthesia will be standardized using sevoflurane, low fresh gas flow, endotracheal intubation, and bispectral index monitoring.
The main outcome will be sevoflurane consumption expressed as mL/kg/hour. Secondary outcomes will include anesthetic agent uptake, time from sevoflurane discontinuation to extubation, and estimated carbon dioxide-equivalent emissions.
The aim is to determine whether pre-emptive local anesthesia can reduce volatile anesthetic requirement and improve early recovery while maintaining adequate anesthetic depth in children undergoing dental general anesthesia.

Start Date01 Aug 2026

Sponsor / Collaborator

Erciyes Üniversitesi

NCT07653490

/ RecruitingNot ApplicableIIT

Evaluation of the Effects of Preoperative Erector Spinae Plane Block Combined With Low-Flow Anaesthesia on Postoperative Quality of Recovery and Opioid Consumption: A Prospective, Randomized, Controlled Study

This prospective randomized controlled study aims to evaluate the effects of preoperative ultrasound-guided erector spinae plane (ESP) block combined with low-flow anaesthesia on postoperative quality of recovery and opioid consumption in patients undergoing elective laparoscopic cholecystectomy. The study will compare postoperative recovery quality, pain scores, analgesic requirements, and perioperative outcomes between patients receiving ESP block with low-flow anaesthesia and those receiving standard anaesthetic management.

Start Date18 Jun 2026

Sponsor / Collaborator-

ChiCTR2600126132

/ Not yet recruitingEarly Phase 1IIT

Exploring the effects and mechanisms of using general anesthetics during the peak period of brain development on children's neurocognition based on metabolomics strategies

Start Date08 Jun 2026

Sponsor / Collaborator

Yibin No. 2 People's Hospital

100 Clinical Results associated with Sevoflurane

100 Translational Medicine associated with Sevoflurane

100 Patents (Medical) associated with Sevoflurane

11,532

Literatures (Medical) associated with Sevoflurane

01 Sep 2026·Medical Gas Research

Anesthetic gas sevoflurane postconditioning alleviates cognitive impairment induced by hemorrhagic shock and resuscitation

Article

Author: Wan, Xiaojing ; Huang, Xiaoci ; Niu, Zhilun ; Hu, Su ; Hu, Xianwen

JOURNAL/mgres/04.03/01612956-202609000-00005/figure1/v/2026-01-09T114759Z/r/image-tiff Sevoflurane is a new type of halogen inhalation anesthetic gas with a rapid induction and emergence. It is widely used for general anesthesia. Previous studies have demonstrated that sevoflurane postconditioning alleviates cerebral ischemia–reperfusion injury and enhances the tolerance of the brain to ischemia and hypoxia. However, whether sevoflurane postconditioning can reduce cerebral ischemia–reperfusion injury caused by hemorrhagic shock and resuscitation and the underlying mechanism are unclear. The present study established cerebral ischemia–reperfusion injury models through an in vivo hemorrhagic shock and resuscitation method in C57BL/6 mice and an in vitro oxygen–glucose deprivation/reoxygenation method in HT22 cells. After hemorrhagic shock and resuscitation treatment, the mice developed significant spatial learning and memory impairments accompanied by aggravated cerebral infarction, whereas sevoflurane postconditioning significantly improved these effects. After in vitro oxygen–glucose deprivation/reoxygenation, the survival rate of HT22 cells was decreased, the apoptosis rate was increased, the expression of silent information regulatory factor 1 was decreased, and the expressions of hypoxia-inducible factor 1α, NOD-like receptor protein 3, gasdermin D, caspase-1, and interleukin-1β were increased. Sevoflurane postconditioning inhibited oxygen–glucose deprivation/reoxygenation-induced changes. Following silent information regulatory factor 1 knockdown by small interfering RNA, the cytoprotective effects of sevoflurane postconditioning were significantly attenuated. These findings suggest that the anesthetic gas sevoflurane postconditioning ameliorates hemorrhagic shock and resuscitation-induced cognitive impairment. This may be mediated by the silent information regulatory factor 1/hypoxia-inducible factor 1α/NOD-like receptor protein 3 pathway.

01 Sep 2026·CLINICAL NEUROPHYSIOLOGY

Corrigendum to “Incidence of epileptiform discharges in children during induction of anaesthesia using Propofol versus Sevoflurane” [Clin. Neurophysiol. 129 (2018) 1642–1648]

Author: Prager, Christine ; Wernecke, Klaus Dieter ; Spies, Claudia ; Fahlenkamp, Astrid ; Rupp, Leopold ; Kramer, Sylvia ; Koch, Susanne ; Mörgeli, Rudolf

01 Sep 2026·CLINICAL NEUROPHYSIOLOGY

Update to: “Incidence of epileptiform discharges in children during induction of anaesthesia using Propofol versus Sevoflurane”

Letter

Author: Prager, Christine ; Wernecke, Klaus Dieter ; Fahlenkamp, Astrid ; Spies, Claudia ; Rupp, Leopold ; Kramer, Sylvia ; Mörgeli, Rudolf ; Koch, Susanne

News (Medical) associated with Sevoflurane

07 Jul 2026

·www.prnewswire.com

Invictus Pharmacy and Mullan Pharmaceutical Inc. Announce Strategic Partnership to Expand Patient Access to FDA-Approved Ganirelix Acetate Injection Through Invictus Pharmacy

Partnership Leverages Invictus Pharmacy's Direct-to-Patient Nationwide Licensed Platform to Deliver FDA-Approved Ganirelix Acetate Injection Across All 50 States NEW YORK, July 7, 2026 /PRNewswire/ -- Invictus Pharmacy, a vertically integrated, nationwide licensed pharmacy platform managed by Invictus Ventures Inc., and Mullan Pharmaceutical Inc., a U.S.-based pharmaceutical company committed to expanding access to affordable, FDA-approved medications through high-capacity manufacturing partnerships and distribution, today announced a strategic partnership to expand patient access to Ganirelix Acetate Injection, 250 mcg/0.5 mL, for patients undergoing fertility treatment across the United States. Continue Reading Mullan Pharma Under the terms of the partnership, Mullan will supply Ganirelix Acetate Injection to Invictus Pharmacy, which, as a licensed dispensing pharmacy, will fulfill valid patient prescriptions through its nationally licensed digital and mail-order pharmacy infrastructure. Through this collaboration, Invictus Pharmacy will help connect fertility patients with this time-sensitive IVF medication with greater speed, transparency, and affordability. Improving Access for Patients During One of Medicine's Most Time-Sensitive Treatments Ganirelix Acetate Injection is a synthetic decapeptide GnRH antagonist indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation (COH) as part of an assisted reproductive technology (ART) protocol, including in vitro fertilization (IVF). The medication is administered as a once-daily subcutaneous injection during the mid-to-late follicular phase of the IVF cycle and plays a pivotal role in synchronizing follicular development, preventing premature ovulation, and optimizing the timing of egg retrieval. For fertility patients, timely, uninterrupted access to Ganirelix Acetate is not merely a matter of convenience — it is clinically essential. Treatment windows are measured in days, and even brief disruptions in medication supply can compromise an entire IVF cycle. This partnership is designed to eliminate those disruptions by ensuring the FDA-approved Ganirelix Acetate Injection is reliably supplied to Invictus Pharmacy, which dispenses it to patients pursuant to valid prescriptions through its nationwide licensed fulfillment platform. Invictus Pharmacy on Patient Access and Affordability "Fertility treatment demands precision. From the clinic, from the physician, and from the pharmacy," said Meyer Davidoff , Founder and Chief Executive Officer of Invictus Pharmacy. "At Invictus, our mission is to remove unnecessary barriers between patients and the medications they are prescribed by combining nationwide licensed pharmacy fulfillment, transparent pricing, and direct collaboration with manufacturers. This partnership reflects the broader purpose of our platform: to create a faster, more affordable, and more reliable prescription access model for patients during moments when timing and trust matter most." Advancing Access to Affordable FDA-Approved Medicines "Mullan's mission is straightforward: expand access to vital and essential medicines for every patient," said Marineh Malek, PharmD, RPh, Chief Pharmaceutical Affairs & Regulatory Compliance Officer, Mullan Pharmaceutical Inc. "Ganirelix Acetate is one of the most time-critical medications in reproductive medicine, and the patients who need it are among the most vulnerable in our healthcare system. Invictus Pharmacy's nationwide licensure, dispensing and fulfillment infrastructure, and commitment to transparent pricing make them an ideal partner to ensure that no patient faces an unnecessary barrier to obtaining this medication." Partnership Highlights The collaboration between Invictus Pharmacy and Mullan Pharmaceutical Inc. delivers tangible benefits to patients, fertility specialists, and the reproductive medicine ecosystem: Nationwide Home Delivery: Invictus Pharmacy holds pharmacy licensure across all 50 U.S. states and territories, enabling home delivery of Ganirelix Acetate Injection to fertility patients regardless of geographic location — eliminating the need for patients to source time-sensitive injectable medications from local specialty pharmacies. Direct-to-Patient Pricing: Consistent with Invictus Pharmacy's model of partnering directly to bypass traditional pharmacy benefit intermediaries, this partnership will enable transparent, competitive pricing for Ganirelix Acetate Injection, reducing out-of-pocket costs for patients at one of the most financially demanding stages of fertility treatment. Seamless Digital Experience: Patients will manage their Ganirelix Acetate prescriptions through Invictus Pharmacy's proprietary e-commerce platform at InvictusPharmacy.com, featuring prescription tracking, price transparency, and digital health program integration. Storage and Fulfillment Expertise: Invictus Pharmacy's advanced platform and pharmacy fulfillment infrastructure are designed to ensure uninterrupted prescription access, with particular attention to the handling requirements of injectable fertility medications. About Ganirelix Acetate Injection Ganirelix Acetate Injection, 250 mcg/0.5 mL, is an FDA-approved, single-dose, sterile, prefilled syringe intended for subcutaneous administration. As a GnRH antagonist, Ganirelix Acetate competitively blocks GnRH receptors on the pituitary gland, inducing rapid and reversible suppression of LH and FSH secretion. It is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation in connection with an ART program. Ganirelix Acetate Injection is a prescription medicine. Pregnancy must be excluded before initiating treatment. Important safety information applies. Patients should consult their reproductive endocrinologist or fertility specialist to determine if Ganirelix Acetate is appropriate for their treatment protocol. Please refer to the full Prescribing Information. About Invictus Pharmacy Founded in 2017, Invictus Pharmacy is a vertically integrated, nationwide pharmacy platform specializing in direct-to-consumer prescription access. Managed by New York–based Invictus Ventures Inc., the company operates a network of retail locations, a nationally licensed mail-order pharmacy, a proprietary e-commerce platform, and a claims adjudication technology system. Invictus Pharmacy has served more than one million patients and holds pharmacy licensure across all 50 U.S. states and territories, with its mail-order facility located in New Jersey. Invictus partners directly with drug manufacturers to deliver transparent, direct-to-consumer pricing on brand and generic medications, bypassing traditional pharmacy benefit intermediaries to lower costs and expand patient access. About Invictus Ventures Inc. Invictus Ventures Inc. is a privately held New York–based healthcare technology and pharmacy management company focused on expanding transparent, affordable prescription access for patients, employers, payers, and drug manufacturers. The company manages Invictus Pharmacy, a vertically integrated, nationwide licensed pharmacy platform with retail, mail-order, digital pharmacy, telehealth, claims adjudication, and direct-to-patient fulfillment capabilities, and is developing the TAB Drug Cost Manager platform, an AI-enabled prescription cost optimization system designed to help employers, self-funded health plans, individuals, and manufacturers identify lower-cost dispensing pathways, The company is headquartered at 150 East 52nd Street, Suite 16003, New York, NY 10022. About Mullan Pharmaceutical Inc. Mullan Pharmaceutical Inc. is a U.S.-based pharmaceutical company focused on expanding access to affordable, FDA-approved medications through high-capacity manufacturing partnerships, product registration, and global distribution. Founded in 2022 as a subsidiary of Pasaca Capital, Mullan brings deep expertise in distribution, operations, and a strong capital base to its mission of ensuring that patients and healthcare providers can reliably access high-quality medications at affordable costs. Mullan's product portfolio includes Ganirelix Acetate Injection, Labetalol Hydrochloride Injection, Argatroban Injection, Sevoflurane, and a range of oral solid dosage forms including Metformin, Gabapentin, Bupropion XL, and Celecoxib. The company is headquartered at 800 E Colorado Blvd., Suite 888, Pasadena, CA. For more information, visit . Forward-Looking Statements: This press release contains forward-looking statements. Actual results may differ materially from those anticipated. SOURCE Invictus Pharmacy 21% more press release views with Request a Demo

License out/in

03 Jun 2026

·www.businesswire.com

Parnell Adds Sevoflurane to Its Growing Veterinary Anesthesia Portfolio

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Parnell today announced the launch of Sevoflurane Inhalation Anesthetic, expanding its anesthesia portfolio to better support veterinary teams across the full procedural workflow. Indicated for the induction and maintenance of general anesthesia in dogs, the new offering provides clinics with a reliable, cost-effective inhalant anesthetic option from a company veterinary teams already rely on. The addition reinforces Parnell’s commitment to delivering confidence at every stage of the anesthetic protocol. With Sevoflurane joining PropofolVet Multidose, Parnell Brand Dexmedetomidine Hydrochloride Injection, CONTRASED™ (atipamezole hydrochloride), and Isoflurane Inhalation Anesthetic, practices can now source a complete anesthesia toolkit from a single, accountable partner. “Veterinary professionals place immense trust in the products they use during anesthesia, and that responsibility drives everything we do,” said Pablo Lamberto, DVM, U.S. General Manager at Parnell. “In a category where consistency and reliability matter as much as cost, the addition of Sevoflurane allows us to better support clinics with dependable, high-quality options across the entire anesthesia protocol.” Key Features Indicated for induction and maintenance of general anesthesia in dogs Nonflammable and nonexplosive, supporting a safer clinical environment Rapid induction and recovery profile consistent with Sevoflurane's established clinical performance Available in 250 mL bottles Competitively priced to support veterinary practices managing anesthesia costs without compromise Supporting the Whole Team Parnell's commitment to veterinary teams extends beyond the product. The Foundations of Anesthesia & Sedation Certificate Program — an online course offering 10 RACE-approved CE hours — is designed to build staff competency and confidence in anesthesia protocols. For practices investing in both clinical excellence and team development, the program complements the portfolio as part of a broader support ecosystem. Learn more at parnell.com/education. For more information about Sevoflurane Inhalation Anesthetic, visit parnell.com/sevoflurane or contact your local distributor representative. About Parnell Parnell is a veterinary pharmaceutical company focused on developing, manufacturing, and commercializing animal health solutions across anesthesia and beyond. With a strong commitment to quality and customer partnerships, Parnell manufactures and markets products for companion and production animals in 10 countries. Learn more at www.parnell.com. ©2026 Parnell Technologies Pty LTD. CONTRASED is a trademark of Parnell Technologies Pty LTD. MKT-26-083 PC US

13 Oct 2025

·www.businesswire.com

University of Michigan study presentation at ANESTHESIOLOGY 2025 supports clinical and environmental benefits of End-tidal Control

The retrospective analysis of nearly 15,000 general anesthesia cases of adults (18 years and older) at the University of Michigan demonstrated End-tidal Control’s association with reduced anesthetic agent usage and greenhouse gas emissions. End-tidal Control is the first and only FDA-approved software that automatically adjusts to maintain end-tidal oxygen and end-tidal anesthetic agent concentrations set by the clinician, with more accuracy in reaching the clinician’s targets versus manual control. The GE HealthCare booth (#1314) at ANESTHESIOLOGY 2025 showcases the company’s advancing perioperative care portfolio that supports clinical workflows and individualized patient care. CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the presentation of findings from the largest real-world evidence study to-date on End-tidal Control anesthesia delivery* software conducted at the University of Michigan. The results demonstrated the environmental and clinical benefits of End-tidal Control software and were presented at ANESTHESIOLOGY® 2025 taking place from October 10-14, in San Antonio, Texas. End-tidal Control software supports the clinician in maintaining clinician-set targets for end-tidal anesthetic agent and oxygen concentrations with greater accuracy than manual adjustments.i End-tidal Control supports low-flow anesthesia,** which may help reduce the amount of anesthetic agent utilized, lowering greenhouse gas emissions and costs.ii “Our research explored the usage and impact of End-tidal Control software in a real-world surgical setting,” said Principal Investigator Douglas Colquhoun, MB ChB, MPH, Assistant Professor of Anesthesiology at the University of Michigan.*** “The findings underscore End-tidal Control’s ability to reduce fresh gas flows, anesthetic agent usage and greenhouse gas emissions, which can improve resource utilization and environmental sustainability.” The retrospective observational study conducted by the University of Michigan analyzed 14,730 general anesthesia cases of adults (18 years and older) to evaluate the usage patterns and impact of End-tidal Control in a hospital setting. Preliminary results showed:iii End-tidal Control utilization in approximately half of the cases (50.5%) at the institution Reductions greater than 35% in fresh gas flow, sevoflurane utilization and carbon dioxide emissions during the maintenance phase of anesthesia** Consistent End-tidal Control usage , with the software active for 82.1% of the anesthesia maintenance phase “Efficient and consistent care delivery is a top priority for healthcare systems today, as workforce shortages and increasingly complex patient needs continue to evolve,” said John Beard, MD, anesthesiologist and Chief Medical Officer of Patient Care Solutions at GE HealthCare. “Automation in anesthetic delivery can reduce variability in care and cognitive burden for clinicians, allowing them to focus on the most critical decisions for their patients. Preliminary findings from the University of Michigan study support the broad applicability of End-tidal Control in a large multisite academic medical center and the real-world results.” In addition to the University of Michigan study, GE HealthCare presented other research at ANESTHESIOLOGY 2025 showcasing the value of End-tidal Control across clinical settings: These conference abstracts support the potential clinical and economic benefits of End-tidal Control software. Additionally, a recent retrospective study from Missouri University Hospital, published in Anesthesiology, shows real-world results of End-tidal Control. The analysis evaluated 238 cases over a six-month period following End-tidal Control implementation compared to manual control, showing decreased fresh gas flow (1.1 L/min in EtC cases vs 2.1 L/min in manual cases).iv The study also showed reduced anesthetic agent usage (9.1 vs 16.6 ml/h – 45.6% reduction),** which resulted in lower greenhouse gas emissions (1.8 vs 3.3 kgCO2e/h) and costs (2.3 vs 4.2 $/h). GE HealthCare designs anesthesia solutions to support care that can think one step ahead. End-tidal Control software can be used with the Aisys™ CS2 Anesthesia Delivery System to enhance perioperative care. For more information on GE HealthCare anesthesia solutions, please visit the company’s booth (#1314) at ANESTHESIOLOGY 2025 or gehealthcare.com. * End-tidal Control in the United States is indicated for patients 18 years of age and older. ** Refer to the anesthetic agent labeling for information regarding indications for use, warnings, and other relevant clinical information specific to that anesthetic agent. For example, labeling for sevoflurane includes specific warnings related to the potential risk associated with use at a low flow rate and under certain clinical conditions. Any decisions regarding selection of anesthetic agent and flow rate should be made at the discretion of the clinician and in their medical judgment based on available information. *** The University of Michigan study was funded by GE HealthCare. The views expressed are solely those of Dr. Douglas Colquhoun, do not reflect the opinions or beliefs of University of Michigan and are based on his own opinions and on results that were achieved in the trial. Since there is no “typical” hospital/clinical setting and many variables exist, i.e. hospital size, case mix, staff expertise, etc. there can be no guarantee that others will achieve the same results. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information. _______________________________ i McCabe MD, Dear GL, Klopman MA, Garg K, Seering MS. End-Tidal Control Versus Manual Control of Inhalational Anesthesia Delivery: A Randomized Controlled Noninferiority Trial. Anesth Analg. 2024 Oct 1;139(4):812-820. https://journals.lww.com/anesthesia-analgesia/fulltext/2024/10000/end_tidal_control_versus_manual_control_of.17.aspx. doi: 10.1213/ANE.0000000000007132. Epub 2024 Jul 19. ii Tay, S., Weinberg, L., Peyton, P., Story, D., and Briedis, J. 2013. “Financial and Environmental Costs of Manual versus Automated Control of End-Tidal Gas Concentrations.” Anaesthesia and Intensive Care 41 (1): 95–101. https://journals.sagepub.com/doi/10.1177/0310057X1304100116. doi:10.1177/0310057X1304100116 iii Colquhoun D, Zhao X, Jewell ES, et al. "Analysis of Use and Outcomes of GE Healthcare End Tidal Control Across a Major US Academic Health System." Conference poster presentation abstract at ANESTHESIOLOGY 2025, San Antonio, Texas, October 12, 2025. https://www.abstractsonline.com/pp8/#!/21028/presentation/7568 iv Mraovic B, Cardonell B, Johnson Q, Luchetti M, Beard JW. Automated Volatile Anesthetics Delivery with End-tidal Control: Early Results from Adoption at Missouri University Hospital. Anesthesiology. 2025 Aug 1;143(2):464-467. https://journals.lww.com/anesthesiology/fulltext/2025/08000/automated_volatile_anesthetics_delivery_with.32.aspx. doi: 10.1097/ALN.0000000000005498. Epub 2025 Jul 8. PMID: 40626802.

Clinical Result

100 Deals associated with Sevoflurane

External Link

KEGG	Wiki	ATC	Drug Bank
D00547	Sevoflurane	N01AB08	DB01236

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	Japan	Maruishi Pharmaceutical Co., Ltd.	20 Apr 1990

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Breast Cancer	Preclinical	United States	Stony Brook University Hospital	02 Jun 2022
Reperfusion Injury	Preclinical	China	Xinjiang Medical University	01 Jan 2016
Alzheimer Disease	Preclinical	Taiwan Province	China Medical University Hospital	01 Jul 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02527083 (CTgov)	Phase 4	Anesthesia \| Hernia \| Acute Pain ... View more	10	Propofol+Ketamine (TIVA-K)	apcgwqoyqd(ftjnfqhqzj) = cbffejzcel grnivbxejw (bqmnhzdkjm, 2.1) View more	-	31 Dec 2025
				Propofol+Remifentanil (TIVA-R)	apcgwqoyqd(ftjnfqhqzj) = dgkdmzhvqo grnivbxejw (bqmnhzdkjm, 0) View more
NCT04950205 (Pubmed \| Front Med (Lausanne))	Early Phase 1	Cognition	71	Sevoflurane post-conditioning	xhmvfwjxos(lweobvirwj) = ffstjmgzyn bbfzfqgdjp (xccfmljtfw, 1.76) View more	Positive	08 Dec 2025
				Propofol-based anesthesia	-
NCT06510803 (Pubmed \| Paediatr Anaesth)	Not Applicable	-	24	Sevoflurane + Sevofluranede (Dräger Apollo)	upkbudcaqb(kbqwuihjxi) = oiabrtcotj rhsavhrnyo (ibenqjptra, 0.3) View more	Negative	01 Jul 2025
				Sevoflurane + Sevofluranede (GE Datex Ohmeda Aisys)	upkbudcaqb(kbqwuihjxi) = soigpassyw rhsavhrnyo (ibenqjptra, 0.4) View more
NCT02697448 (CTgov)	Not Applicable	Atrial Fibrillation	135	Propofol (Propofol)	cxzlqkqlhh(eymdmcqzwy) = fphcykamep eoqthdnkfr (ajoasavyzt, wqruriaavl - dbqtzcvmfc) View more	-	20 Aug 2024
				sevoflurane (Sevoflurane)	cxzlqkqlhh(eymdmcqzwy) = wjqfcjhqgc eoqthdnkfr (ajoasavyzt, kuzcoajznz - vxzhicuuag) View more
NCT02053766 (CTgov)	Not Applicable	Mitochondrial Diseases	19	Dexmedetomidine (Dexmedetomidine (Precedex®))	dcpwtdvqsf = pmolunzdhh dkejazdmqt (tzozeihctp, xgpwbupfni - dzybwtovjt) View more	-	17 Jul 2024
				propofol (Propofol)	dcpwtdvqsf = qghnghtids dkejazdmqt (tzozeihctp, cetsvdvwgy - qdtknvsfyk) View more
DDW2024	Not Applicable	-	-	maintenance sevoflurane (Induction sevoflurane)	nrsazzrbtq(jikvsirwrj) = igmfjxbjkw iwzgvltqfo (rqshbdehkk )	-	21 May 2024
				Maintenance sevoflurane	nrsazzrbtq(jikvsirwrj) = bnzlqdkubv iwzgvltqfo (rqshbdehkk )
NCT04355962 (Pubmed \| Ann Intensive Care) Manual	Phase 3	COVID-19 IL-6	60	Sevoflurane sedation	vfezzsafxl(mpnazqsnhi) = kfgdtdbcsz wtvkwwfqum (uykpqaybvf ) View more	Negative	27 Mar 2024
				Continuous intravenous sedation	vfezzsafxl(mpnazqsnhi) = agcrykhcof wtvkwwfqum (uykpqaybvf ) View more
NCT02604459 (OPCare, CTgov)	Not Applicable	Anesthesia \| Emergence Delirium \| Hip Fractures	145	General anesthesia+fentanyl+propofol+sevoflurane (Mini Mental State Exam)	zuwxzsbwgs(luwicoqfqm) = npxcmvnhca bpxvycxkgc (qmtbdkasmd, 0.49) View more	-	17 Oct 2023
				General anesthesia+fentanyl+propofol+sevoflurane (Tested and Excluded)	mpqvfsqmlr(kptdtuipdn) = isgxyqttnl ypbafljelw (dhojpvtwue, lmeosnzdmh - dcpldsbpll) View more
NCT02660411 (ChiCTR-IPR-15006209, Pubmed \| Br J Anaesth)	Not Applicable	-	1,228	Propofol-based i.v. anaesthesia	ixbdiksfbg(oncmdnogft): adjusted hazard ratio = 1.02 (95% CI, 0.83 - 1.26), P-Value = 0.834 View more	Negative	01 Aug 2023
				Sevoflurane-based inhalational anaesthesia
NCT02662257 \| ChiCTR-IPR-15006209 (Pubmed)	Not Applicable	Delirium	1,228	Propofol-based anaesthesia	meofxoectz(feasrnsrlf) = rdzoilihsz iowogbrzhe (ojbkisbhjo )	Positive	01 Aug 2023
				Sevoflurane-based anaesthesia	meofxoectz(feasrnsrlf) = mcocvbqgwx iowogbrzhe (ojbkisbhjo )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Sevoflurane

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation